Brief: Everest Medicines Announces Agreement With Visara
30/10/2025 01:25
Oct 30 (Reuters) - Everest Medicines Ltd 1952.HK: AGREEMENT WITH VISARA TO DEVELOP AND COMMERCIALIZE VIS-101 IN GREATER CHINA AND OTHER ASIAN MARKETS TO PAY US$7 MILLION UPFRONT Further company coverage: 1952.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region